Psychiatric medications: Adverse cutaneous drug reactions

Clinics in Dermatology

Volumn 31, Issue 1, 2013, Pages 101-109

  Bliss, Sarah A ^a   Warnock, Julia K ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MAPROTILINE; MIRTAZAPINE; NEFAZODONE; OLANZAPINE; OXCARBAZEPINE; PAROXETINE; PROTRIPTYLINE; PSYCHOTROPIC AGENT; RISPERIDONE; SERTRALINE; TOPIRAMATE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ACNE; ADVERSE OUTCOME; ALOPECIA; ANAMNESIS; ANGIONEUROTIC EDEMA; DERMATITIS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; ERYTHRODERMA; HOSPITALIZATION; HUMAN; HYPERHIDROSIS; MEDICAL DECISION MAKING; NOTE; PATIENT ASSESSMENT; PATIENT SAFETY; PHOTOSENSITIVITY; PIGMENT DISORDER; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSYCHOPHARMACOTHERAPY; RELAPSE; SEBORRHEA; SEBORRHEIC DERMATITIS; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; TREATMENT WITHDRAWAL; URTICARIA;

ANTIPSYCHOTIC AGENTS; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTROPIC DRUGS; SKIN DISEASES; TIME FACTORS;

EID: 84871065694     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2011.11.014     Document Type: Note

References (110)

1. Svensson C.K., Cowen E.W., Gaspari A.A. Cutaneous drug reactions. Pharmacol Rev 2001, 53:357-379.
2. Gu Q., Dillon C.F., Burt V.L. Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. NCHS Data Brief 2010, 42:1-8.
3. Kessler R.C., Chiu W.T., Demler O., et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:617-627.
4. Culy C.R., Goa K.L. Lamotrigine. A review of its use in childhood epilepsy. Paediatr Drugs 2000, 2:299-330.
5. Messenheimer J.A., Giorgi L., Risner M.E. The tolerability of lamotrigine in children. Drug Saf 2000, 22:303-312.
6. Schaub N., Bircher A.J. Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro. Allergy 2000, 55:191-193.
7. Yalçin B., Karaduman A. Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid. J Am Acad Dermatol 2000, 43:898-899.
8. Guberman A.H., Besag F.M., Brodie M.J., et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999, 40:985-991.
9. Schlienger R.G., Shapiro L.E., Shear N.H. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998, 39:S22-S26.
10. Page R.L., O'Neil M.G., Yarborough D.R., et al. Fatal toxic epidermal necrolysis related to lamotrigine administration. Pharmacotherapy 1998, 18:392-398.
11. Sachs B., Rönnau A.C., von Schmiedeberg S., et al. Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatology 1997, 195:60-64.
12. Li L.M., Russo M., O'Donoghue M.F., et al. Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk. Arqu Neuropsiquiatr 1996, 54:47-49.
13. Troost R.J., Van Parys J.A., Hooijkaas H., et al. Allergy to carbamazepine: parallel in vivo and in vitro detection. Epilepsia 1996, 37:1093-1099.
14. Dam M. Practical aspects of oxcarbazepine treatment. Epilepsia 1994, 35:23-25.
15. Beran R.G. Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993, 34:163-165.
16. Qin P., Nordentoft M. Suicide risk in relation to psychiatric hospitalization: evidenced based on longitudinal. Arch Gen Psychiatry 2005, 62:427-432.
17. Srebrnik A., Hes J.P., Brenner S. Adverse cutaneous reactions to psychotropic drugs. Acta Derm Venereol Suppl (Stockh) 1991, 158:1-12.
18. Basler R.S., Goetz C.S. Synergism of minocycline and amitriptyline in cutaneous hyperpigmentation. J Am Acad Dermatol 1985, 12:577. [letter].
19. Ming M.E., Bhawan J., Stefanato C.M., et al. Imipramine-induced hyperpigmentation: four cases and a review of the literature. J Am Acad Dermatol 1999, 40:159-166.
20. Hashimoto K., Joselow S.A., Tye M.J. Imipramine hyperpigmentation: a slate-gray discoloration caused by long-term imipramine administration. J Am Acad Dermatol 1991, 25:357-361.
21. Atkin D.H., Fitzpatrick R.E. Laser treatment of impramine-induced hyperpigmentation. J Am Acad Dermatol 2000, 43:77-80.
22. Steele T.E., Ashby J. Desipramine-related slate-gray skin pigmentation. J Clin Psychopharmacol 1993, 13:76-77. [letter].
23. Narurkar V., Smoller B.R., Hu C.H., et al. Desipramine-induced blue-gray photosensitive pigmentation. Arch Dermatol 1993, 129:474-476.
24. Tunca Z., Tunca M.I., Dilsiz A., et al. Clomipramine- induced pseudocyanotic pigmentation. Am J Psychiatry 1989, 146:552-553.
25. MacMorran W.S., Krahn L.E. Adverse cutaneous reactions to psychotropic drugs. Psychosomatics 1997, 38:413-422.
26. Lineberry T.W., Peters G.E., Bostwick J.M. Bupropion-induced erythema multiforme. Mayo Clin Proc 2001, 76:664-666.
27. Hemlock C., Rosenthal J.S., Winston A. Fluoxetine-induced psoriasis. Ann Pharmacother 1992, 26:211-212.
28. Barth J.H., Baker H. Generalized pustular psoriasis precipitated by trazodone in the treatment of depression. Br J Dermatol 1986, 115:629-630.
29. Skonicki J.J., Warnock J.K. Drug Eruptions. Curr Psychiatry 2008, 7:43-51.
30. Gaufberg E., Ellison J.M. Photosensitivity reaction to fluoxetine. J Clin Psychiatry 1995, 56:486. [letter].
31. Gillet-Terver M.N., Modiano P., Tréchot P., et al. Fluvoxamine photosensitivity. Australas J Dermatol 1996, 37:62.
32. Epstein J.H., Wintroub B.U. Photosensitivity due to drugs. Drugs 1985, 30:42-57.
33. Cooper G.L. The safety of fluoxetine: an update. Br J Psychiatry Suppl 1988, 3:77-86.
34. Miller L.G., Bowman R.C., Mann D., et al. A case of fluoxetine-induced serum sickness. Am J Psychiatry 1989, 146:1616-1617.
35. Warnock J.K., Sieg K., Willsie D., et al. Drug-related alopecia in patients treated with tricyclic antidepressants. J Nerv Ment Dis 1991, 179:441-442.
36. McCollom R.A., Elbe D.H., Ritchie A.H. Bupropion-induced serum sickness-like reaction. Ann Pharmacother 2000, 34:471-473.
37. Peloso P.M., Baillie C. Serum sickness-like reaction to bupropion. JAMA 1999, 282:1817. [letter].
38. Yolles J.C., Armenta W.A., Alao A.O. Serum sickness induced by bupropion. Ann Pharmacother 1999, 33:931-933.
39. Tripathi A., Greenberger P.A. Bupropion hydrochloride induced serum sickness-like reaction. Ann Allergy Asthma Immunol 1999, 83:165-166.
40. Taniguchi S., Hamada T. Photosensitivity and thrombocytopenia due to amitriptyline. Am J Hematol 1996, 53:49-50.
41. Ljunggren B., Bojs G. A case of photosensitivity and contact allergy to systemic tricyclic drugs, with unusual features. Contact Dermatitis 1991, 24:259-265.
42. Case J.D., Yusk J.W., Callen J.P. Photosensitive reaction to phenelzine: a case report. Photodermatol 1988, 5:101-102.
43. Ogilvie A.D. Hair loss during fluoxetine treatment. Lancet 1993, 342:1423. [letter].
44. Gupta S., Major L.F. Hair loss associated with fluoxetine. Br J Dermatol 1991, 159:737-738.
45. Seifritz E., Hatzinger M., Müller M.J., et al. Hair loss associated with fluoxetine but not with citalopram. Can J Psychiatry 1995, 40:362. [letter].
46. Bourgeois J.A. Two cases of hair loss after sertraline use. J Clin Psychopharmacol 1996, 16:91-92.
47. Bhatara V.S., Gupta S., Freeman J.W. Fluoxetine associated paresthesias and alopecia in a woman who tolerated sertraline. J Clin Psychiatry 1996, 57:227. [letter].
48. Parameshwar E. Hair loss associated with fluvoxamine use. Am J Psychiatry 1996, 153:581-582.
49. Alanko K. Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis 1993, 29:254-257.
50. Welykyj S., Gradini R., Nakao J., Massa M. Carbamazepine-induced eruption histologically mimicking mycosis fungoides. J Cutan Pathol 1990, 17:111-116.
51. Dooley J., Camfield P., Gordon K., et al. Lamotrigine-induced rash in children. Neurology 1996, 46:240-242.
52. Roberts D.L., Marks R. Skin reactions to carbamazepine. Arch Dermatol 1981, 117:273-275.
53. Brenner S., Wolf R., Landau M., et al. Psoriasiform eruption induced by anticonvulsants. Isr J Med Sci 1994, 30:283-286.
54. Ghadirian A.M., Lalinec-Michaud M. Report of a patient with lithium-related alopecia and psoriasis. J Clin Psychiatry 1986, 47:212-213.
55. Hyson C., Sadler M. Cross sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci 1997, 24:245-249.
56. Wong I.C., Mawer G.E., Sander J.W. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999, 33:1037-1042.
57. Wong I.C., Mawer G.E., Sander J.W. Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom. Epilepsia 2001, 42:237-244.
58. Richens A. Safety of lamotrigine. Epilepsia 1994, 35:S37-S40.
59. Sander J.W., Trevisol-Bittencourt P.C., Hart Y.M. The efficacy and long term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Res 1990, 7:226-229.
60. Srebrnik A., Bar-Nathan E.A., Ilie B., et al. Vaginal ulcerations due to lithium carbonate therapy. Cutis 1991, 48:65-66.
61. DeToledo J.C., Minagar A., Lowe M.R., et al. Skin eruption with gabapentin in a patient with repeated AED-induced Stevens-Johnson's syndrome. Ther Drug Monit 1999, 21:137-138.
62. Kimyai-Asadi A., Harris J.C., Nousari H.C. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999, 60:714-725.
63. Harth Y., Rapoport M. Photosensitivity associated with antipsychotics, antidepressants, and anxiolytics. Drug Saf 1996, 14:252-259.
64. Gold M.S., Sweeney D.R. Perphenazine-induced systemic lupus erythematosus-like syndrome. J Nerv Ment Dis 1978, 166:442-445.
65. Eberlein-König B., Bindl A., Przybilla B. Phototoxic properties of neuroleptic drugs. Dermatology 1997, 194:131-135.
66. Nigen S., Knowles S.R., Shear N.H. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol 2003, 2:279-299.
67. Korkij W., Soltani K. Fixed drug eruption. A brief review. Arch Dermatol 1984, 120:520-524.
68. Hamann G.L., Egan T.M., Wells B.G., et al. Injection site reactions after intramuscular administration of haloperidol decanoate 100mg/mL. J Clin Psychiatry 1990, 51:502-504.
69. Reilly G.D., Wood M.L. Prochlorperazine-an unusual cause of lip ulceration. Acta Derm Venereol 1984, 64:270-271.
70. Shear N.H., Knowles S.R., Sullivan J.R., et al. Cutaneous reactions to drugs. Fitzpatrick's dermatology in general medicine 2003, 1330-1337. McGraw-Hill, New York. 6th ed. I.M. Freedbury, A.Z. Eisen, K. Wolff, K.F. Austen, L.A. Goldsmith, S. Katz (Eds.).
71. Chosidow O.M., Stern R.S., Wintroub B.U. Cutaneous drug reactions. Harrison's principles of internal medicine 2005, 318-324. McGraw-Hill, New York. 16th ed. D.L. Kasper, E. Braunwald, A.S. Fauci (Eds.).
72. Moore D.E. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002, 25:345-372.
73. Berger H. Pigmentation after thioridazine. Arch Dermatol 1969, 100:487. [letter].
74. Ban T.A., Guy W., Wilson W.H. Neuroleptic-induced skin pigmentation in chronic hospitalized schizophrenic patients. Can J Psychiatry 1985, 30:406-408.
75. Zelickson A.S. Skin pigmentation and chlorpromazine. JAMA 1965, 194:670-672.
76. Garnis-Jones S. Dermatologic side effects of psychopharmacologic agents. Dermatol Clin 1996, 14:503-508.
77. Bond W.S., Yee G.C. Occular and cutaneous effects of chronic phenothiazines therapy. Am J Hosp Pharm 1980, 37:74-78.
78. Wolf M.E., Richer S., Berk M.A., et al. Cutaneous and ocular changes associated with the use of cholorpromazine. Int J Clin Pharmacol Ther Toxicol 1993, 31:365-367.
79. Wernicke J.F. The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985, 46:59-67.
80. Gales B.J., Gales M.A. Erythema multiforme and angioedema with indapamide and sertraline. Am J Hosp Pharmacy 1994, 51:118-119.
81. Camisa C., Grines C. Amoxapine: a cause of toxic epidermal necrolysis?. Arch Dermatol 1983, 119:709-710.
82. Simpson G.H., Pi E.H., Sramek J.J. Neuroleptics and anti-psychotics. Meyer's side effects of drugs 1982, 95-108. Elsevier, Amsterdam. M.N.G. Dukes (Ed.).
83. Friedmann P.S., Strickland I., Pirmohamed M., et al. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994, 130:598-604.
84. Herbert A.A., Ralston J.P. Cutaneous reactions to anticonvulsant medications. J Clin Psychiatry 2001, 62:22-26.
85. Yoon Y., Jagoda A. New antiepileptic drugs and preparations. Emerg Med Clin North Am 2000, 18:755-765.
86. Panuska J.R., King T.R., Korenblat P.E., et al. Hypersensitivity reaction to desipramine. J Allergy Clin Immunol 1987, 80:18-23.
87. Cullinan S.A., Bower G.C. Acute pulmonary hypersensitivity to carbamazepine. Chest 1975, 68:580-581.
88. Powell W.J., Koch-Weser J., Williams R. Lethal hepatic necrosis after therapy with imipramine and despipramine. JAMA 1968, 206:642-645.
89. Troost R.J., Oranje A.P., Lijnen R.L., et al. Exfoliative dermatitis due to immunologically confirmed carbamazepine hypersensitivity. Pediatr Dermatol 1996, 13:316-320.
90. Miranda-Romero A., Pérez-Olivia N., Aragoneses H., et al. Carbamazepine hypersensitivity syndrome mimicking mycosis fungoides. Cutis 2001, 67:47-51.
91. Schlienger R.G., Shear N.H. Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998, 39:S3-S7.
92. Tennis P., Stern R.S. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997, 49:542-546.
93. Scerri L., Shall L., Zaki I. Carbamazepine-induced anticonvulsant hypersensitivity syndrome-pathogenic and diagnostic considerations. Clin Exp Dermatol 1993, 18:540-542.
94. Okuyama R., Ichinohasama R., Tagami H. Carbamazepine induced erythroderma with systemic lymphadenopathy. J Dermatol 1996, 23:489-494.
95. Sarzi-Puttini P., Panni B., Cazzola M., et al. Lamotrigine-induced lupus. Lupus 2000, 9:555-557.
96. De Vriese A.S., Philippe J., Van Renterghem D.M., et al. Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature. Medicine (Baltimore) 1995, 74:144-151.
97. Sterker M., Berrouschot J., Schneider D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharmacol Ther 1995, 33:595-597.
98. Chaffin J.J., Davis S.M. Suspected lamotrigine-induced toxic epidermal necrolysis. Ann Pharmacother 1997, 31:720-723.
99. Fogh K., Mai J. Toxic epidermal necrolysis after treatment with lamotrigine (Lamictal). Seizure 1997, 6:63-65.
100. Pavlidakey G.P., Hashimoto K., Heller G.L., et al. Chlorpromazine-induced lupus-like disease: case report and review of the literature. J Am Acad Dermatol 1985, 13:109-115.
101. McNevin S., MacKay M. Chlorprothixene-induced systemic lupus erythematosus. J Clin Psychopharmacol 1982, 2:411-412.
102. Scuderi S., Gift T.E. Thiothixene induced edema. Psychiatr Med 1986, 4:249-252.
103. Bachot N., Roujeau J.C. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003, 4:561-572.
104. Milionis H.J., Skopelitou A., Elisaf M.S. Hypersensitivity syndrome caused by amitriptyline administration. Postgrad Med J 2000, 76:361-363.
105. Raz A., Bergman R., Eilam O., et al. A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 2001, 321:156-158.
106. Vittorio C.C., Muglia J.J. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995, 155:2285-2290.
107. Scerri L., Shall L., Zaki I. Carbamazepine-induced anticonvulsant hypersensitivity syndrome: pathogenic and diagnostic considerations. Clin Exp Dermatol 1993, 18:540-542.
108. Horneff G., Lenard H.G., Wahn V. Severe adverse reaction to carbamazepine: significance of humoral and cellular reactions to the drug. Neuropediatrics 1992, 23:272-275.
109. Robbie M.J., Scurry J.P., Stevenson P. Carbamazepine-induced severe systemic hypersensitivity reaction with eosinophilia. Drug Intell Clin Pharm 1988, 22:783-784.
110. Oakley A.M., Hodge L. Cutaneous vasculitis with maprotiline. Aust N Z J Med 1985, 15:256-257.